Di Zh y yo (688192.SH): Sh w zh h go ru zh du xing yn ji chng gu r xun 2025 nin sh ji fi i d hu. Di Zhe Pharmaceutical (688192.SH): The research results of Shuo Zhe and Gao Rui Zhe were selected for the 2025 World Lung Cancer Congress.

Smart Financial News APP reports that Dixher Medicine (688192.SH) announced that the company will unveil its independently developed new lung cancer targeted drug ZEGFROVY (ZEGFROVY, generic name: osimertinib tablets) and highly selective JAK1 inhibitor GORIVY (generic name: golvatinib capsules) at the 2025 World Lung Cancer Conference (WCLC) in Barcelona, Spain, from September 6th to 9th, 2025. The company will present multiple latest research results on the treatment of non-small cell lung cancer. Among them, the latest data from the international multi-center registered clinical study of ZEGFROVY "Wu Kong 1B" (WU-KONG1B) has been selected for oral presentation.